drugset / Trial / NCT02466009

Regorafenib in Metastatic Colorectal Cancer

NCT02466009 ↗

Phase 2 Completed 27 enrolled University of Rochester Bayer · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to measure high grade (3-5) toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer.

Timeline

Start
2015-03
Primary completion
2019-07
Completion
2022-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Regorafenib Small molecule 120 mg Oral

Indications